Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.						
	Substitute fo	or form 1449B	/PTO	,	Complete if Known	7
	INFORMATI	ON DISCLO	SURE	Application Number	09/913,728	
	STATEMEN	T BY APPLI	ICANT	Filing Date	10/23/2001	JUN 2 3 2004
	Date Submit	tod: June 23	2004	First Named Inventor	Toshio KITAMURA	et al
	Date Submit	icu. <u>June 23</u>	<u>, 2004</u>	Group Art Unit	1647	B. S.
	(use as many s	sheets as ne	cessary)	Examiner Name	R. DeBerry	Busculat
Sheet	1	of	1	Attorney Docket Number	084335-0143	AUCH

				U.S. PATENT DOCUMENTS	•	
Examiner Initials*		U.S. Patent	Document	Name of Patentee or Applicant of Cited Document	Date of Publication of	Pages, Columns, Lines, Where Relevant
	Cite No. ¹	Number	Kind Code ² (if known)			Passages or Relevant Figures Appear

		<u></u> _		F	OREIGN PATENT DOCUMEN	TS	· · · · · · · · · · · · · · · · · · ·	
Examiner Initials*	Cite No.1	Fore Office ³	eign Patent [Number ⁴	Ocument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	٦٥
								-

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
10	A1	LUO, Hong, et al., "An amino acid substitution in the <i>Drosophila hop lum-1</i> Jak kinase causes leukemia-like hematopoletic defects", <u>The EMBO Journal</u> , vol. 14, no. 7, pp 1412-1420, Oxford University Press, 1995	
	A2	LACRONIQUE, Virginie, et al., "A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia", <u>Science</u> , vol. 278, Nov. 14, 1997, pp 1309-1312	
	A3	MEYDAN, Naftaly, et al., "Inhibition of acute lymphoblastic leukaemia by a JAK-2 inhibitor", <u>Nature</u> , vol. 379, Feb. 15, 1996, pp 645-648	
			,

Examiner Signature Date Considered	8/11/04

*EXAMINER: Initial if reference considered, whether or not criation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 002.1215153.1